文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早产儿视网膜病变激光与抗血管内皮生长因子治疗后的肺动脉高压

Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

这项多中心回顾性队列研究纳入2010至2020年美国48家儿童医院新生儿重症监护病房中胎龄22 0/7至31 6/7周、因早产儿视网膜病变接受抗血管内皮生长因子治疗或激光光凝的1577例早产儿。倾向评分匹配982例后,抗血管内皮生长因子组与激光组相比肺动脉高压治疗率在调整医院和年份后无统计学显著差异(调整比值比1.62,95%置信区间0.90-2.89,P=0.10)。作者认为抗血管内皮生长因子暴露可能与肺动脉高压相关,但不能排除残余混杂,未来研究似乎有必要。

要点

  • 匹配后抗血管内皮生长因子组肺动脉高压治疗率6.7%(95%置信区间2.6-6.9) vs 激光组4.3%(95%置信区间4.4-10.2),调整后无统计学显著差异。
  • 调整医院和年份后,抗血管内皮生长因子与肺动脉高压治疗风险的调整比值比为1.62(95%置信区间0.90-2.89,P=0.10)。
  • 作者认为抗血管内皮生长因子暴露可能与肺动脉高压相关,但不能排除基于全身合并症或医院实践差异的残余混杂。

核心结论

  • 调整医院和年份后,抗血管内皮生长因子治疗与肺动脉高压治疗(肺血管扩张剂使用)无统计学显著关联。
  • 作者认为抗血管内皮生长因子暴露可能与肺动脉高压相关,但不能排除基于全身合并症或医院实践差异的残余混杂。
  • 作者认为未来研究这一可能的不良反应似乎有必要。

研究设计与样本

  • 多中心回顾性队列研究,数据来自2010至2020年美国48家儿童医院新生儿重症监护病房的儿科健康信息系统数据库。
  • 纳入胎龄22 0/7至31 6/7周、因早产儿视网膜病变接受抗血管内皮生长因子治疗或激光光凝的早产儿1577例(55.9%男性)。
  • 689例接受激光光凝,888例接受抗血管内皮生长因子治疗(95%贝伐珠单抗,5%雷珠单抗)。
  • 首次治疗早产儿视网膜病变的中位月经后年龄为36.4周(四分位距34.6-38.7)。
  • 倾向评分匹配982例(每组491例),协变量平衡良好(模型方差比1.15),并调整出生年份和医院。

主要发现

  • 匹配后抗血管内皮生长因子组肺动脉高压治疗率为6.7%(95%置信区间2.6-6.9),激光组为4.3%(95%置信区间4.4-10.2)。
  • 调整医院和年份后,抗血管内皮生长因子与肺动脉高压治疗的调整比值比为1.62(95%置信区间0.90-2.89,P=0.10),无统计学显著差异。
  • 研究还纳入30日龄后接受超声心动图检查的比值以调整肺动脉高压筛查的时代趋势和医院间差异。

局限性

  • 作者指出不能排除基于全身合并症或医院实践差异的残余混杂。
  • 作者认为未来研究这一可能的不良反应似乎有必要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anti-vascular endothelial growth factor (VEGF) therapy for retinopathy of prematurity (ROP) has potential ocular and systemic advantages compared with laser, but we believe the systemic risks of anti-VEGF therapy in preterm infants are poorly quantified. OBJECTIVE: To determine whether there was an association with increased risk of pulmonary hypertension (PH) in preterm infants with ROP following treatment with anti-VEGF therapy as compared with laser treatment. DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective cohort study took place at neonatal intensive care units of 48 children's hospitals in the US in the Pediatric Health Information System database from 2010 to 2020. Participants included preterm infants with gestational age at birth 22 0/7 to 31 6/7 weeks who had ROP treated with anti-VEGF therapy or laser photocoagulation. EXPOSURES: Anti-VEGF therapy vs laser photocoagulation. MAIN OUTCOMES AND MEASURES: New receipt of pulmonary vasodilators at least 7 days after ROP therapy was compared between exposure groups, matched using propensity scores generated from preexposure variables, and adjusted for birth year and hospital. The odds of receiving an echocardiogram after 30 days of age was also included to adjust for secular trends and interhospital variation in PH screening. RESULTS: Among 1577 patients (55.9% male) meeting inclusion criteria, 689 received laser photocoagulation and 888 received anti-VEGF treatment (95% bevacizumab, 5% ranibizumab). Patients were first treated for ROP at median 36.4 weeks' postmenstrual age (IQR, 34.6-38.7). A total of 982 patients (491 in each group) were propensity score matched. Good covariate balance was achieved, as indicated by a model variance ratio of 1.15. More infants who received anti-VEGF therapy were treated for PH, but when adjusted for hospital and year, this was no longer statistically significant (6.7%; 95% CI, 2.6-6.9 vs 4.3% 95% CI, 4.4-10.2; adjusted odds ratio, 1.62; 95% CI, 0.90-2.89; P = .10). CONCLUSIONS AND RELEVANCE: Anti-VEGF therapy was not associated with greater use of pulmonary vasodilators after adjustment for hospital and year. Our findings suggest exposure to anti-VEGF may be associated with PH, although we cannot exclude the possibility of residual confounding based on systemic comorbidities or hospital variation in practice. Future studies investigating this possible adverse effect seem warranted.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Nitkin CR, Bamat NA, Lagatta J, et al. Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity. JAMA Ophthalmol. 2022. PMID: 36201183. doi:10.1001/jamaophthalmol.2022.3788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。